(Alliance News) - AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025.
The Cambridge-based pharmaceuticals firm said revenue in 2024 rose 18% to USD54.07 billion from USD45.81 billion in 2023. It helped pretax profit surge 26% to USD8.69 billion from USD6.90 billion. At constant exchange rates, total revenue rose 21%. Reported earnings per share rose 18% to USD4.54 from USD3.84 and core EPS by 13% to USD8.21 from USD7.26.
"Our company delivered a very strong performance in 2024 with total revenue and core EPS up 21% and 19% respectively. We also delivered nine positive high value phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025," Chief Executive Officer Pascal Soriot commented.
In the fourth quarter, revenue rose 24% to USD14.89 billion from USD12.02 billion and pretax profit near doubled to USD1.67 billion from GBP897 million. EPS increased 56% to USD0.97 from USD0.62, with core EPS up 44% to USD2.09 from USD1.45.
Shore Capital analyst Sean Conroy said fourth-quarter revenue was 5% ahead of consensus and core EPS 1% above forecast.
In response, shares in AstraZeneca rose 5.1% to 11,692.00 pence each in London on Thursday morning. The wider FTSE 100 index was up 0.9%.
Oncology sales rose 27% in the quarter to USD6.34 billion, 4% ahead of consensus, with Tagrisso up 20%, Calquence up 20% and Enhertu up 48%.
Cardiovascular, renal and metabolism sales rose 16% to USD3.14 billion, with Farxiga up 21% and Lokelma up 35%.
Respiratory & Immunology sales rose 27% to USD2.13 billion, Vaccines and Immune sales rose 58% to USD651 million and Rare Diseases sales rose 21% to USD2.38 billion.
By region, US sales increased 28 to USD6.53 billion and Europe sales rose 37% to USD3.95 billion. Emerging Markets sales rose 13% to USD3.13 billion, including a 1% drop in China to USD1.36 billion.
For 2025, AstraZeneca expects revenue growth to ease to a high single-digit percentage at constant currency. It added: "If foreign exchange rates for February 2025 to December 2025 were to remain at the average rates seen in January 2025, it is anticipated that total revenue in FY 2025 would incur a low single-digit percentage adverse impact compared to the performance at CER."
The FTSE 100 listing declared a second interim dividend of USD2.10 per share, a rise of around 6.6% from USD1.97 a year prior. It makes for an annual dividend of USD3.10 per share, up 6.9% from USD2.90. The payout is to be further increased this year, with a dividend of USD3.20 expected.
Astra also expects to up capital expenditure by some 50%, "driven by manufacturing expansion projects and investment in IT systems".
CEO Soriot added: "This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver USD80 billion total revenue by the end of the decade. In 2025 alone, we anticipate the first phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines."
AstraZeneca also said it received a notice about suspended unpaid import taxes in China in January for USD900,000.
AstraZeneca believes these taxes relate to its cancer drugs Imfinzi and Imjudo.
A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable," it said. "AstraZeneca continues to fully cooperate with the Chinese authorities."
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.